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Vitamin D deficiency further increases the risk of osteoporosis in HIV-positive patients coinfected with hepatitis C virus (HCV);
however, it is still unclear whether HCV-related increased fracture risk is a function of the severity of liver disease. The aim of this
review was to identify studies on associative vitamin D deficiency patterns in high-risk populations such as HIV/HCV coinfected
patients. We did this by searchingMEDLINE and EMBASE databases, from inception to August 2014, and included bibliographies.
The final 12 articles selected are homogeneous in terms of age but heterogeneous in terms of sample size, participant recruitment,
and data source. Most of the HIV/HCV coinfected patients have less than adequate levels of vitamin D. After reviewing the selected
articles, we concluded that vitamin D deficiency should be regarded as a continuum and that the lower limit of the ideal range
is debatable. We found that vitamin D deficiency might influence liver disease progression in HIV/HCV coinfected patients.
Methodological issues in evaluating vitamin D supplementation as a relatively inexpensive therapeutic option are discussed, as
well as the need for future research, above all on its role in reducing the risk of HCV-related fracture by modifying liver fibrosis
progression.
1. Introduction
Clinicians and researchers are currently using available data
sets to assess the balance of beneficial and harmful effects of
vitamin D not only on skeletal health but also on its potential
role in nonskeletal outcomes such as cardiovascular disease,
death, and quality of life [1–3].
The effects of vitamin D on immune function [4] and its
immunomodulatory and anti-inflammatory properties have
been recognized, and a nontraditional role of vitamin D has
been reported in cancer patients and autoimmune disease [4–
6].
These effects have also been reported in chronic liver
disease and among chronic hepatitis C patients in whom
vitamin D is involved in regulating the immune system,
inflammatory response, and fibrogenesis [7–10].
Recently, low 25-Hydroxyvitamin D serum levels have
been associated with the severity of liver fibrosis in genotype
1 chronic hepatitis C patients (G1CHC) [11, 12].
In vitro studies have shown that vitamin D is an antiviral
agent that inhibits HCV production in a human hepatoma
cell line [13]; a synergistic effect of vitamin D and interferon-
alfa on HCV production has also been reported. In HCV
monoinfected patients with recurrent hepatitis C after liver
transplant, higher rates of virologic response were observed
in those receiving vitamin D supplementation [14].
Finally, in a randomized prospective trial including only
CHC treatment-naive HCV-genotype (HCV-GT) 1 patients,
virologic response rates were again higher in the group
receiving vitamin D supplementation [11].
Hepatitis C virus (HCV) infection has become a major
health problem among the HIV-infected population [15, 16].
Approximately 30% of all human immunodeficiency virus
Hindawi Publishing Corporation
International Journal of Endocrinology
Volume 2015, Article ID 969040, 7 pages
http://dx.doi.org/10.1155/2015/969040
2 International Journal of Endocrinology
(HIV-) positive patients are also infected with hepatitis C
virus (HCV) [16–18].
Among the multifactorial mechanisms underlying skele-
tal disorder in the HIV and HCV setting, vitamin D defi-
ciency is considered a risk factor for osteoporotic fracture
[7, 18–20]; moreover, the finding that HCV-related increased
fracture risk is a function of the severity of liver disease has
generated a lot of attention so far [7, 21–23].
The fact that HIV and HIV/HCV coinfected patients are
at risk of vitamin D deficiency because a wide variety of
medications used to treat AIDS/HIV enhance the catabolism
of 25(OH)D and 1,25(OH) 2D [23, 24] has been acknowl-
edged. Vitamin D deficiency and bone disease in HAART
patients [25] have been associated with NNRTIs [26], as well
as tenofovir [27] and PIs [27, 28].
While there are recommendations for the evaluation,
treatment, and prevention of vitamin D deficiency in healthy
patients at risk of deficiency [3, 24] and in specific HIV
populations such as young HIV-positive adults with 25-
hydroxyvitamin D (25-OHD) < 20 ng/mL [29], there is still
some debate about the evaluation, treatment, and prevention
of vitamin D deficiency in the HIV population [30] and in
particular in HIV/HCV coinfected subjects [7, 8, 31, 32].
Finally, recent literature offers recommendations on
screening and treating vitaminD deficiency and osteoporosis
in HIV-positive patients [30] but there is not a great deal
of literature and/or consensus on cost-effective management
of this patient population, especially HIV/HCV coinfected
patients [22, 31–33].
This paper aims to summarize the prevalence of vita-
min D deficiency in HIV/HCV coinfected patients, review
available data on the association between vitamin D levels
and severity of liver disease, and discuss the impact of this
relatively inexpensive therapy on reducing liver fibrosis and
improving sustained virologic response rate (SVR) in HCV
patients.
2. Methods
We searched the Medline (PubMed) database for articles
that matched any combination of the following keywords:
vitamin D, vitamin D deficiency, 25-hydroxyvitamin D,
HIV/HCV coinfections and diagnosis and treatment, and
hypovitaminosis. Studies were identified through searching
MEDLINE and EMBASE databases, from their inception to
August 2014.
Articles were screened and those that reported on the
relationship between vitamin D insufficiency/deficiency and
HIV/HCV coinfections were included. We limited the search
to language (i.e., Spanish, French, or English) and abstract
availability. Because the terms HIV infection and HIV/HCV
infection are frequently associated in the scientific literature,
for this study the term HIV/HCV coinfections was used
as a medical subject heading (MeSH) and the other terms
(together with their linguistic variations) were used as key-
words. Some articles that appeared with keyword searching
were excluded because they were not relevant to the purpose
of this review and tackled other topics such as anti-HCV
therapy in HIV/HCV coinfected patients.
3. Results
Forty-four studies fit the criteria; 15 of these were duplicates
and were removed. After screening titles and abstracts, we
excluded 9 articles on studies involving HCV monoinfected
or HIV monoinfected participants. Applying the eligibility
criteria, the full texts of 12 articles were reviewed.
We selected 12 studies (see Table 1): 10 original [21, 31–
39], 1 systematic review and meta-analysis article [22], and
1 review manuscript [20].
We found 5 cross-sectional [31, 32, 35, 37, 39], 3 retrospec-
tive [21, 34, 36], and 2 prospective cohort studies [33, 38];
most control groups included patients with HIV-mono- or
HCV-monoinfection.
Overall, the articles were highly heterogeneous in terms
of sample size, participant recruitment, and data source
(Table 1). The patients’ age in all the studies is relatively
homogenous (median age 45 years old), reflecting the world-
wide aging of the HIV population after the widespread
availability of combination antiretroviral therapy (cART).
In general, the articles analyzed the prevalence of vitamin
D levels in HIV/HCV coinfected patients and the association
between vitaminD deficiency and liver disease variables such
as severity of liver disease [21, 32, 34, 39] and the influence of
vitamin D levels on virological response [32, 35, 36].
In fact, two recent studies showed a significant association
between hypovitaminosis D, severity of liver disease, and
response to interferon- (IFN-) based treatment in HIV-HCV
patients [11, 35]. However, the association between 25(OH)D
levels and SVR rates is thought to be limited to difficult-to-
treat patients inwhom treatment failuremay depend on other
factors (IL28 B, HCV genotype, hepatic expression of vitamin
D receptor) [11, 12, 33, 35].
In their HIV/HCV coinfected setting, Branch et al. [36]
found that baseline levels of 25(OH)D in patients treatedwith
ritonavir are not predictors of EVRand SVRbecause ritonavir
may influence conversion of 25(OH)D to the active metabo-
lite. Other articles showed a significant negative association
between longer duration of ART, especially PI exposure
and bone mineral density (BMD) and osteoporosis [22, 28,
38]. However, in one large cohort study, HCV coinfection
remained an independent predictor of osteoporotic fractures
after checking for the presence of cirrhosis [21, 22].
Two articles [33, 39] showed no association between
hypovitaminosis D, low BMD, and liver fibrosis (histolog-
ical fibrosis staging according to METAVIR scores 0 [no
fibrosis] to 4 [cirrhosis]) in HIV/HCV coinfected patients.
The analysis of patient setting showed that most of the
study populations included HIV/HCV coinfected African
Americans. How race affects the impact of vitaminD on bone
health has recently been investigated in African American
men and women, revealing differences due to socioeconomic
and genetic factors, such as resistance to the bone resorbing
effects of PTH in the black population [33, 40–42].
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Most of the patients enrolled in Milazzo et al.’s study [39]
had HCV GT1 genotype and low levels of vitamin D that
varied seasonally, as reported in another Italian study [9].
On the contrary, Avihingsanon et al. [32] found signif-
icant liver fibrosis in patients with HIV/HCV coinfection
and low levels of 25(OH)D. These results may be influenced
by race (Asian), HCV genotype (GT) [the most prevalent
circulating genotype was HCV GT3 (47%)], and IL28B
polymorphism (themajor allele [CC genotype] of rs12979860
position was found in 88% of HIV/HCV patients).
Regarding the prevalence of fracture in this group of
patients with liver disease, Dong et al.’s systematic review
and meta-analysis [22] highlights that fracture incidence rate
ratios (IRRs) are higher for coinfected than HIV monoin-
fected and uninfected patients. In multivariate analyses of
HIV/HCV coinfected individuals, older age, lower BMI,
postmenopausal status, and time on protease inhibitor were
significantly associated with osteoporosis [18–20, 22, 27, 28,
38].
Among theHIV/HCVcoinfected patients, haemophiliacs
are considered to be at the highest risk for fracture. Table 1
includes Linari et al.’s study [37] on the prevalence of
osteoporosis in this group of patients. The authors divided
78 haemophiliac patients into three groups (uninfected, HIV
monoinfected, and HIV/HCV coinfected); hypovitaminosis
D and low BMD were present in all patients, with lower
L-DXA scores in coinfected patients and a more evident
increase of bone resorption markers in HIV and HIV/HCV
coinfected patients.
4. Discussion
Our literature review indicated that vitamin D deficiency is
common in HIV/HCV coinfected patients and that hypovi-
taminosis D occurrence among patients with an average age
of 45 years should raise concerns about the risk of developing
bone fractures.
Low levels of vitamin D were also found in HIVmonoin-
fected [21, 38, 39] and HCV monoinfected control groups
[32, 37].
However, the selected articles reveal some aspects that
prompt us to reconsider the definition of hypovitaminosis D.
In fact, the significance of vitamin D deficiency has several
limitations because 25-hydroxyvitamin D concentrations
varied by age, season, study sample size, and methodological
assay approach [25(OH)D assay used] [37, 39, 40]. Moreover,
black and Hispanic individuals synthesize less vitamin D
per unit of sun exposure than white individuals [33, 41,
42]. Therefore, levels of vitamin D in HIV/HCV coinfected
patients should be monitored according to the reference
range for the sample setting. In fact, further validation of the
reported results is needed, since studies conducted on larger
cohorts, as well as in Italian coinfected patients [39], have
revealed low vitamin D levels consistent with those recently
reported for healthy populations from Western countries
[38, 39, 43].
Milazzo et al. found that season and severity of fibrosis
were predictors of low 25(OH)D in an Italian HIV/HCV
coinfected population and that median 25(OH)D serum
levels below 25 ng/mL were similar in the HIV monoin-
fected, HIV/HCV coinfected, and healthy controls [39]. In
a recent, large study on a general healthy population in
Central Europe, Pludowski et al. [43] reported an average
concentration of less than 30 ng/mL of 25(OH)D.
Guidelines specify that 25(OH)D concentrations are the
best indicator of overall vitamin D status in the general
population and define vitamin D insufficiency as a 25(OH)D
level of below 75 nmol/L (30 ng/mL) and deficiency as below
50 nmol/L (20 ng/mL) [40]. However, the Endocrine Society
Clinical Practice Guidelines (ESCPG) suggest that the vita-
minD requirements of sick patientsmay be greater than those
of healthy individuals, and blood levels above 30 ng/mL may
carry additional health benefits by reducing the risk of various
disease conditions [24, 40].
The Hormone Foundation’s Patient Guide to Vitamin D
Deficiency suggests that patients with chronic (long-term)
liver disease are at high risk of deficiency; therefore vitaminD
testing is recommended and patients should be given advice
about adequate dietary intake and medical supplementation
to prevent and treat deficiency [44].
The influence of diet on vitamin D status is minimal
(accounting for 3.7–5.9𝜇g or 148–236 IU daily) as only a
few foods, such as sardines, tuna, and mushrooms, naturally
contain vitaminD [24, 40]. Today, themain sources are foods
which have been fortified with vitamin D2 and/or vitamin
D3, such as milk, orange juice, yoghurt, cheese, and breakfast
cereals, which people of all ages can include in their daily
diet. Although it has been suggested that a Mediterranean-
style diet or a diet rich in fish and other foods containing
vitamin D has health benefits, further evaluation is necessary
[24, 38, 44, 45].
Our selected articles investigated the possibility of an
association between vitaminDdeficiency and hepatic fibrosis
in HIV/HCV coinfected patients. One particular study that
involved mostly African American HIV–HCV coinfected
patients showed that increasing vitamin D levels does not
improve bone or liver outcome [33], whereas other studies
illustrate how vitamin D influences virological response to
antiviral treatment in HIV-HCV coinfected patients and has
a role in liver fibrosis progression [31, 34, 35].
Older and more recent research has investigated the link
between vitamin D homeostasis and bone loss in patients
with liver disease [7, 8, 22, 46]. Vitamin D deficiency in
chronic liver disease is only partly the result of a synthesis
dysfunction of the liver or/and decreased vitamin D absorp-
tion caused by intestinal edema due to portal hypertension or
to cholestasis.
Recently, significantly lower levels of 25-hydroxyvitamin
D were observed in patients with liver cirrhosis, admitted for
acute decompensation, suggesting that systemic inflamma-
tion or liver dysfunction has an impact on 25(OH)D level
[46].
Regarding vitamin D synthesis, parathyroid hormone
(PTH) is involved in its activity and expression; disturbance
of the parathyroid hormone-vitamin D axis with bone mass
loss in chronic liver disease has recently been reported in
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cirrhotic postmenopausal women and in geriatric patients
with vitamin D deficiency [47, 48].
A systematic review and meta-analysis included in our
literature review found that HIV/HCV-coinfected patients
are at higher risk for osteoporosis and fractures than HIV-
monoinfected controls and are at a substantially higher risk
than uninfected controls. HCV and viral hepatitis coinfection
remained an independent predictor of osteoporosis [22].
HCV and HIV infections are both associated with
increased levels of proinflammatory cytokines that can pro-
mote osteoclastogenesis or inhibit osteoblast differentiation
and collagen synthesis [7, 8, 22].
The mechanisms responsible for osteopenia and osteo-
porosis are uncertain and multifactorial, but exposure to
certain antiretroviral drugs (in particular a NRTI: tenofovir-
TDF-and the PI class), aging, HIV itself, parathormone
(PTH) increase, and vitamin D deficiency may be implicated.
Moreover, in a cohort of G1CHC patients, the hepatic
expression of VDR protein is associated with severity of both
liver fibrosis and inflammation [12, 34].
Guidelines for the management of osteoporosis in HIV-
negative [3, 24, 40, 44] and HIV-positive patients identified
adequate vitamin D status, in addition to calcium from diet
or supplements, as essential for the prevention of osteoporosis
[24, 29, 30, 49]. Adjunct therapy with high-dose, daily vitD3
for HIV-infected subjects and for those on/off highly active
antiretroviral therapy was recently investigated in a high-
risk, adult HIV-infected group and in HIV-infected children
[29, 49]. However, these levels have not been supported by
adequate dose-finding RTC studies.
Our review highlights important areas to explore for
future prevention strategies. Future interferon-free direct-
acting agents may have a better effect on bone metabolism
and decrease fracture incidence after successful treatment.
Although the risk of fracture is clearly higher in HIV/HCV
coinfected individuals, it is not clear if DXA screening of
these individuals before the age of 50 is a cost-effective
prevention method and requires further study.
Lifestyle-related factors appear to have a substantial
impact on the risk of fractures in HIV/HCV coinfected
individuals but, based upon available studies, this cannot
solely be attributed to alcohol and substance use [22, 38].
Recent data indicate that vitamin D supplementation is
a relatively inexpensive therapeutic option to reduce liver
fibrosis and improve SVR [22, 34]. Interestingly, two poten-
tially modifiable factors, CD4+ nadir and serum 25(OH)D
levels, were both independent modulators of liver fibrosis
progression and determinants of portal pressure [34].
Currently, practitioners are often concerned about the
lack of well-characterized data on the therapeutic value of
vitamin D supplementation to reduce liver fibrosis progres-
sion in HIV/HCV coinfected patients. Increasing vitamin
D intake may positively modulate response to antiviral
treatment in HCV-infected or HIV/HCV coinfected patients,
and, in association with standardized treatment for chronic
liver disease, it could be of benefit in reducing liver fibrosis
progression in HIV/HCV coinfected patients.
In general, there is no evidence to suggest that increasing
the recommended vitamin D intake for the general popu-
lation to 20–50𝜇g (800–2000 IU) would cause any medical
problems. However, the authors recommend careful clinical
observation and laboratory monitoring when higher doses
of vitamin D supplements are administered because of the
long half-life of vitamin D accumulation in tissues; excessive
intake of vitamin D can cause chronic toxic effects, which
present ashypercalcemia and renal damage.
Further controlled randomized trials on the effects of
vitamin D supplementation are warranted to assess the rele-
vance of vitaminD for liver fibrosis progression inHIV/HCV
coinfected patients.
5. Conclusions
Our review indicates that vitamin D supplementation can
be considered a relatively inexpensive therapeutic option to
lower HCV-related fracture risk, owing to its benefic effect in
reducing liver fibrosis progression in HIV/HCV coinfected
patients. Other determinants of HCV-related increased frac-
ture risk have still to be defined.
A good compromise between different opinions could
be to start with relatively higher doses of vitamin D in
HIV-HCV infected patients, skipping some steps of dose
supplementation until more information is available to settle
the question.
What Is New?
What Is Known?
(i) Experimental evidence suggested a hepatoprotective
role of vitamin D.
(ii) Practitioners are often concerned about the lack of
well-characterized data on the therapeutic value of
Vitamin D supplementation to reduce liver fibrosis
progression in HIV/HCV coinfected patients.
What Is New?
(i) Only particularly low levels of vitamin D should be
considered in HIV/HCV coinfected patients.
(ii) This systematic review reveals a recent interest in
vitaminD supplementation as a relatively inexpensive
therapeutic option to reduce HCV-related increased
fracture risk by modifying liver fibrosis progression.
What Does This Mean?
(i) Among HIV-infected patients, the association
between 25(OH)D levels and severity of liver disease
partly explains the HCV-associated increased risk
of osteoporotic fractures, while other determinants
have still to be defined.
(ii) Further RCTs are warranted to determine what level
of vitamin D insufficiency and deficiency places an
individual at risk of cirrhosis evolutions and what is
the optimal dosage of vitamin D3 to exert sufficient
antifibrosis effects in HIV/HCV coinfected popula-
tions.
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vitamin D deficiency diagnosed after introduction of antiretro-
viral therapy including efavirenz in a patient living at latitude
59 degrees,” AIDS, vol. 20, no. 14, pp. 1906–1907, 2006.
[27] K. Childs, C. Kadish, W. Branch-Elliman, S. Fishman, M.
Mullen, and A. Branch, “Vitamin D and calcium supplements
reverse the secondary hyperparathyroidism that commonly
International Journal of Endocrinology 7
occurs inHIVpatients onTDF containingHAART,” in Proceed-
ings of the 15th Annual Conference of the BritishHIVAssociation,
vol. 10, p. 40, HIV Medication, Liverpool, UK, 2009, Abstract
P89.
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